abacavir
Selected indexed studies
- Abacavir. (Drugs, 1998) [PMID:9585869]
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. (Lancet, 2017) [PMID:28867497]
- Abacavir hypersensitivity reaction: an update. (Ann Pharmacother, 2008) [PMID:18303141]
_Worker-drafted node — pending editorial review._
Connections
abacavir is a side effect of
Sources
- Abacavir. (1998) pubmed
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. (2017) pubmed
- Abacavir hypersensitivity reaction: an update. (2008) pubmed
- Abacavir-induced liver toxicity. (2016) pubmed
- Lamivudine/zidovudine/abacavir: triple combination tablet. (2003) pubmed
- Abacavir pharmacogenetics--from initial reports to standard of care. (2013) pubmed
- Abacavir and cardiovascular disease: A critical look at the data. (2016) pubmed
- An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV. (2022) pubmed
- Abacavir and lamivudine combination. (2009) pubmed
- Abacavir hypersensitivity. (2008) pubmed